Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 20...
March 01 2021 - 8:30AM
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will release financial results and business updates for the
fourth quarter and fiscal year ended December 31, 2020 on Monday,
March 8, 2021. The Company will host a webcast and conference call
that day at 8:30 a.m. Eastern Time to discuss these results and
updates.
The live call may be accessed by dialing (877) 312-5845
(domestic) or (765) 507-2618 (international) and referring to
conference ID number 5663077. A live webcast of the conference call
will be available online in the Investors and Media section of the
Company’s website at ir.minervaneurosciences.com. The archived
webcast will be available on the Company’s website beginning
approximately two hours after the event for 30 days.
The live webcast can be accessed under “Events and
Presentations” in the Investors and Media section of Minerva’s
website at ir.minervaneurosciences.com. The archived webcast will
be available on the website beginning approximately two hours after
the event for 90 days.
About Minerva Neurosciences
Minerva’s portfolio of compounds includes: roluperidone
(MIN-101), in clinical development for schizophrenia, and MIN-301,
in pre-clinical development for Parkinson’s disease. Minerva’s
common stock is listed on the NASDAQ Global Market under the symbol
“NERV.” For more information, please visit
www.minervaneurosciences.com.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Sep 2023 to Sep 2024